TY1B-GR1 Antibody

What is the anti-Gr-1 antibody and what cell populations does it target?

The anti-Gr-1 antibody (clone RB6-8C5) is a rat IgG2b antibody that recognizes the myeloid differentiation antigen Gr-1, a glycosylphosphatidyl inositide-linked protein. This antibody binds to both Ly6G, which is predominantly expressed on neutrophils, and Ly6C, which is additionally expressed on monocytes, macrophages, T-cell subsets, eosinophils, and small-vessel endothelial cells . While primarily used for neutrophil depletion, researchers should be aware that anti-Gr-1 has affinity for Ly6C and may affect additional immune cell populations beyond neutrophils .

What are the standard protocols for anti-Gr-1 antibody administration in mouse models?

For effective neutrophil depletion in mouse models, standard protocols typically involve intraperitoneal injections of anti-Gr-1 antibody at 4 mg/kg. Timing is crucial, with initial administration often given at 2 hours post-intervention (such as after spinal cord injury or tumor inoculation), followed by a second dose at 24 hours . Alternative dosing schedules that have shown efficacy include 200 μg administered every other day for up to 4 weeks, or 250 μg every 3 days, depending on the research model and depletion duration required . Researchers should establish appropriate dosing schedules based on their specific model, as antibody efficacy may vary by mouse strain, age, and disease context.

How can researchers verify successful depletion after anti-Gr-1 antibody administration?

Verification of successful depletion requires multiple assessment methods:

• Complete blood counts: To quantify reduction in circulating neutrophils (expect >90% reduction with anti-Gr-1)

• Flow cytometry: To assess cell populations in blood, spleen, bone marrow, and target tissues

• Blood smear analysis: To confirm morphological characteristics of remaining neutrophils

• Intravital and confocal microscopy: For direct visualization of neutrophil behavior in vivo (e.g., examining rolling and adhering neutrophils in exposed veins and venules)

Researchers should be cautious about potential masking effects, as RB6-8C5-bound cells may emerge in the Ly6C^mid-Ly6G^− gate, potentially mimicking successful depletion while these antibody-bound cells may retain some functional capacity .

How do the kinetics of neutrophil depletion and recovery differ between anti-Gr-1 and anti-Ly6G antibodies?

The kinetics of neutrophil depletion and recovery show important differences between these antibodies:

Both antibodies show a "rebound" effect after a few days of treatment, leading to neutrophilia that may complicate longer-term studies . This rebound effect appears to be associated with increased neutrophil production in the bone marrow, as evidenced by the higher proportion of BrdU-positive (newly generated) neutrophils in the circulation after antibody treatment .

What are the unexpected consequences of anti-Gr-1 antibody treatment on non-myeloid cell populations?

While anti-Gr-1 is primarily used for neutrophil depletion, researchers have observed significant impacts on T cell populations, particularly the memory T cell compartment. Anti-Gr-1 administration has been shown to affect CD8+ effector memory T cells (T^em^), which express Gr-1 antigen and can be targeted by the antibody . This leads to complex outcomes in cancer models:

• Despite partial depletion of CD8+ T^em^ cells, remaining cells show increased tumor-specific interferon-gamma (IFN-γ) production

• The proliferative drive in T cells appears to exceed the depleting properties of the anti-Gr-1 antibodies

• Changes in T^em^ populations may contribute to initial delays in tumor growth but potentially limit long-term anti-tumor efficacy

These findings highlight the importance of comprehensive immune monitoring beyond the targeted neutrophil population when using anti-Gr-1 antibodies in complex disease models.

How does anti-Gr-1 antibody treatment affect experimental outcomes in cancer immunotherapy models?

In cancer immunotherapy models, particularly when combined with lymphodepletion, reconstitution and active-specific tumor cell vaccination (LRAST), anti-Gr-1 antibody treatment produces complex effects:

• Enhanced tumor-specific T cell responses: LRAST combined with anti-Gr-1 mAb administration enhances the induction of tumor-specific T cells in tumor vaccine draining lymph nodes (TVDLN) capable of releasing IFN-γ in a tumor-specific manner

• Delayed tumor growth: Additional anti-Gr-1 mAb administration in LRAST-treated mice delayed growth of D5 melanomas by approximately two weeks

• Impact on different MDSC populations: The antibody completely depletes polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in peripheral blood within 2-4 days after treatment initiation, but monocytic MDSC (M-MDSC) populations are reduced but not completely depleted

• Potential therapeutic limitations: While initially effective, the persisting portion of RB6-8C5-bound cells might continue to exert immunosuppressive properties, and the impact on memory T cell compartments may limit long-term anti-tumor efficacy

These findings suggest that anti-Gr-1 administration can improve standard cancer treatment regimens, but optimal protocols must consider both timing and combination with other immunotherapeutic approaches.

What paradoxical effects have been observed in neutrophil depletion studies using anti-Gr-1 in inflammatory conditions?

In inflammatory models, particularly spinal cord injury (SCI), anti-Gr-1 treatment has revealed counterintuitive outcomes challenging the traditional view of neutrophils as purely detrimental in acute inflammation:

• Worsened neurological outcomes: Despite >90% reduction in circulating neutrophils and significantly reduced neutrophil infiltration into injured spinal cord tissue, anti-Gr-1 treated mice showed worsened behavioral outcomes as measured by the Basso Mouse Scale and subscores after SCI

• Impaired wound healing: Treatment with anti-Gr-1 reduced astrocyte reactivity (a critical wound healing response), resulted in less spared white matter, and diminished axonal preservation compared to isotype controls

• Alterations in growth factors and chemokines: The negative outcomes may be related to changes in factors essential for wound healing and tissue repair

These findings suggest that neutrophils may play beneficial roles in certain inflammatory contexts, promoting wound healing and limiting lesion propagation. Researchers must carefully consider the potential for context-dependent neutrophil functions when designing depletion studies.

What methodological considerations should researchers address when interpreting anti-Gr-1 depletion studies?

Several critical methodological considerations must be addressed when designing and interpreting anti-Gr-1 depletion studies:

• Antibody persistence: Anti-Gr-1 antibodies can persist on the cell surface of MDSCs for up to 4 days and may retain suppressive activity despite appearing to be depleted by standard flow cytometry analyses

• Flow cytometry artifacts: RB6-8C5-bound cells may shift in apparent phenotype, appearing in the Ly6C^mid-Ly6G^− gate while potentially retaining functional capacity

• Kinetics of depletion: The short window of efficacy and rebound effects necessitate careful timing of experimental endpoints and potentially repeated dosing

• Strain and context variability: Efficacy varies by mouse strain (C57BL/6 mice are particularly refractory to anti-Ly6G) and disease context

• Off-target effects: Impacts on T cell subsets and other Ly6C-expressing cells must be monitored and accounted for in experimental design and interpretation

• Control selection: Using appropriate isotype-matched control antibodies is essential, as is including comprehensive time-course analyses

Addressing these methodological considerations will strengthen experimental design and facilitate more accurate interpretation of results from neutrophil depletion studies.